Palmieri R, Candoni A, Di Raimondo F et al (2025) Navigating acute myeloid leukemia towards better outcomes: treatment pathways and challenges for patients ineligible for intensive chemotherapy. Blood Rev 101288. https://doi.org/10.1016/j.blre.2025.101288

Shimony S, Stahl M, Stone RM (2025) Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol 100:860–891. https://doi.org/10.1002/ajh.27625

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pratz KW, Jonas BA, Pullarkat V et al (2024) Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol 99:615–624. https://doi.org/10.1002/ajh.27246

Article  CAS  PubMed  Google Scholar 

Wei AH, Döhner H, Pocock C et al (2020) Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 383:2526–2537. https://doi.org/10.1056/NEJMoa2004444

Article  CAS  PubMed  Google Scholar 

DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617–629. https://doi.org/10.1056/NEJMoa2012971

Article  CAS  PubMed  Google Scholar 

Siegel RL, Kratzer TB, Giaquinto AN et al (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10–45. https://doi.org/10.3322/caac.21871

Article  PubMed  PubMed Central  Google Scholar 

Sperotto A, Bochicchio MT, Simonetti G et al (2023) Measurable residual disease and clonal evolution in acute myeloid leukemia from diagnosis to post-transplant follow-up: the role of next-generation sequencing. Biomed 11:359. https://doi.org/10.3390/biomedicines11020359

Article  CAS  Google Scholar 

Kim N, Hahn S, Choi YJ et al (2024) Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes. Cancer Cell Int 24:174. https://doi.org/10.1186/s12935-024-03368-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han HJ, Choi K, Suh HS (2024) Impact of aging on acute myeloid leukemia epidemiology and survival outcomes: a real-world, population-based longitudinal cohort study. PLoS ONE 19:e0300637. https://doi.org/10.1371/journal.pone.0300637

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao L, Zhao J, Zhong K et al (2022) Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther 7. https://doi.org/10.1038/s41392-022-00966-4

Li X, Song Y (2020) Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol Oncol 13. https://doi.org/10.1186/s13045-020-00885-3

Chen C, Feng Y, Zhou C et al (2024) Development of natural product-based targeted protein degraders as anticancer agents. Bioorg Chem 153. https://doi.org/10.1016/j.bioorg.2024.107772

Hu Y, Yan Y, Wang J et al (2024) Molecular glue degrader for tumor treatment. Front Oncol 14. https://doi.org/10.3389/fonc.2024.1512666

Long X, Zhao L, Li G, et al (2021) Identification of GSPT1 as prognostic biomarker and promoter of malignant colon cancer cell phenotypes via the GSK-3β/CyclinD1 pathway. Aging 13. https://doi.org/10.18632/aging.202796

Sellar RS, Sperling AS, Stabicki M et al (2022) Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells. J Clin Invest 132

Matyskiela ME, Lu G, Ito T et al (2016) A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 535. https://doi.org/10.1038/nature18611

Chengdu FenDi Pharmaceutical Co., Ltd. (2024) A phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and initial efficacy of FD-001 in patients with relapsed or refractory hematological malignancies. https://clinicaltrials.gov. Accessed 12 Mar 2025

Celgene (2024) A phase 1, open-label, dose finding study of CC-90009, a novel cereblon E3 ligase modulating drug, in subjects with relapsed or refractory acute myeloid leukemia or relapsed or refractory higher-risk myelodysplastic syndromes. https://clinicaltrials.gov. Accessed 12 Mar 2025

Monte Rosa Therapeutics, Inc (2025) A phase 1/2 study of oral MRT-2359 in patients with MYC-Driven and other selected solid tumors including lung cancer and diffuse B-Cell lymphoma. https://clinicaltrials.gov. Accessed 12 Mar 2025

Biotheryx, Inc. (2023) An open label, escalating multiple dose study to evaluate the safety, toxicity, pharmacokinetics, and preliminary activity of BTX-1188 in subjects with advanced malignancies. https://clinicaltrials.gov. Accessed 12 Mar 2025

Paudel RR, Lu D, Chowdhury SR et al (2023) Targeted protein degradation via lysosomes. Biochem 62. https://doi.org/10.1021/acs.biochem.2c00310

Hsia O, Hinterndorfer M, Cowan AD et al (2024) Targeted protein degradation via intramolecular bivalent glues. Nature 627. https://doi.org/10.1038/s41586-024-07089-6

Neklesa TK, Winkler JD, Crews CM (2017) Targeted protein degradation by PROTACs. Pharmacol Ther 174. https://doi.org/10.1016/j.pharmthera.2017.02.027

Surka C, Jin L, Mbong N et al (2021) CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood 137:661–677. https://doi.org/10.1182/blood.2020008676

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu S, Qiao X, Wu S et al (2022) c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia. Apoptosis: Int J Program Cell Death 27. https://doi.org/10.1007/s10495-022-01756-7

Lasica M, Anderson MA (2021) Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med 11:463. https://doi.org/10.3390/jpm11060463

Article  PubMed  PubMed Central  Google Scholar 

Nwosu GO, Ross DM, Powell JA, Pitson SM (2024) Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death Dis 15:413. https://doi.org/10.1038/s41419-024-06810-7

Article  PubMed  PubMed Central  Google Scholar 

Nishida Y, Ishizawa J, Ayoub E, et al (2023) Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv 9:eadh1436. https://doi.org/10.1126/sciadv.adh1436

Röhner L, Ng YLD, Scheffold A et al (2021) Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of CrbnI391V. Exp Hematol 93. https://doi.org/10.1016/j.exphem.2020.11.004